Vanguard Group Inc. Reduces Position in DaVita Inc. (NYSE:DVA)

Key Points

• Vanguard Group Inc. reduced its stake in DaVita Inc. by 3.1%, owning 5,054,064 shares worth approximately $773 million after selling 160,751 shares in the latest quarter.
• DaVita reported a quarterly earnings per share of $2.95, surpassing analysts’ estimates of $2.70, with revenue of $3.38 billion, reflecting a year-over-year growth of 6.1%.
• Analysts have mixed ratings for DaVita, with Barclays lowering their target price to $160, while Wall Street Zen upgraded the stock from "hold" to "buy."

Vanguard Group Inc. cut its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 3.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,054,064 shares of the company's stock after selling 160,751 shares during the quarter. Vanguard Group Inc. owned about 6.58% of DaVita worth $773,120,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the period. Copia Wealth Management acquired a new position in DaVita during the fourth quarter valued at $30,000. Coppell Advisory Solutions LLC lifted its position in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares during the period. Canada Post Corp Registered Pension Plan acquired a new position in DaVita during the fourth quarter valued at $55,000. Finally, GeoWealth Management LLC lifted its position in DaVita by 30.6% during the fourth quarter. GeoWealth Management LLC now owns 525 shares of the company's stock valued at $79,000 after purchasing an additional 123 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by company insiders.

DaVita Price Performance

Shares of DaVita stock traded up $0.96 during trading hours on Friday, reaching $135.35. The stock had a trading volume of 721,001 shares, compared to its average volume of 925,075. The stock's 50 day moving average is $139.68 and its 200 day moving average is $145.28. The firm has a market capitalization of $9.68 billion, a PE ratio of 13.31, a PEG ratio of 0.97 and a beta of 1.09. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the prior year, the firm posted $2.00 earnings per share. The company's revenue was up 6.1% compared to the same quarter last year. Equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of a number of research reports. Truist Financial set a $148.00 target price on shares of DaVita in a research report on Friday, August 8th. Barclays decreased their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.